Heidelberg Pharma Advances HDP-101 in Clinical Trial for Multiple Myeloma

Heidelberg Pharma AG has initiated Cohort 9 in its Phase I/IIa trial, focusing on HDP-101, a lead Antibody Drug Conjugate (ADC) candidate for treating relapsed or refractory multiple myeloma. This progression follows a successful Cohort 8, where no dose-limiting toxicities were reported, and a favorable safety profile was maintained.

An escalated dose of 175 µg/kg is now administered in Cohort 9. Notably, Cohort 8 demonstrated early evidence of clinical activity, with one patient experiencing a very good partial response. This adds to the success of Cohort 5, where a patient achieved complete remission. Such outcomes underline HDP-101's therapeutic potential in heavily pretreated patients.

The study aims to assess HDP-101's safety, tolerability, and efficacy in patients with multiple myeloma or other BCMA-expressing disorders, contributing valuable insights into the treatment of this challenging condition.